(EVK) Evonik Industries - Overview

Sector: Basic Materials | Industry: Specialty Chemicals | Exchange: XETRA (Germany) | Market Cap: 7.624m EUR | Total Return: -8.9% in 12m

Stock Specialty Chemicals, Additives, Nutrition, Materials, Polymers
Total Rating 45
Safety 79
Buy Signal 0.45
Specialty Chemicals +12.7
Specialty Chemicals +5.7
Market Cap: 8,836m
Avg Trading Vol: 24.2M EUR
ATR: 3.11%
Peers RS (IBD): 62.5
Risk 5d forecast
Volatility29.0%
Rel. Tail Risk-4.99%
Reward TTM
Sharpe Ratio-0.49
Alpha-15.46
Character TTM
Beta0.016
Beta Downside0.266
Drawdowns 3y
Max DD39.76%
CAGR/Max DD0.02
EPS (Earnings per Share) EPS (Earnings per Share) of EVK over the last years for every Quarter: "2021-03": 0.51, "2021-06": 0.54, "2021-09": 0.58, "2021-12": 0.49, "2022-03": 0.76, "2022-06": 0.75, "2022-09": 0.54, "2022-12": 0.2, "2023-03": 0.25, "2023-06": 0.26, "2023-09": 0.41, "2023-12": -0.13, "2024-03": 0.42, "2024-06": 0.5, "2024-09": 0.58, "2024-12": 0.16, "2025-03": 0.59, "2025-06": 0.34, "2025-09": 0.27, "2025-12": 0.15,
EPS CAGR: -35.13%
EPS Trend: -34.7%
Last SUE: 0.65
Qual. Beats: 0
Revenue Revenue of EVK over the last years for every Quarter: 2021-03: 3358, 2021-06: 3636, 2021-09: 3871, 2021-12: 4090, 2022-03: 4498, 2022-06: 4772, 2022-09: 4878, 2022-12: 4340, 2023-03: 4005, 2023-06: 3886, 2023-09: 3771, 2023-12: 3605, 2024-03: 3796, 2024-06: 3930, 2024-09: 3832, 2024-12: 3599, 2025-03: 3777, 2025-06: 3499, 2025-09: 3391, 2025-12: 3403,
Rev. CAGR: -7.17%
Rev. Trend: -88.6%
Last SUE: 0.73
Qual. Beats: 0
Description: EVK Evonik Industries

Evonik Industries AG is a German specialty chemicals company with global operations. The companys business model focuses on developing and producing high-margin chemical products for various industries.

Its segments include Specialty Additives, providing materials for coatings and lubricants; Nutrition & Care, which supplies ingredients for animal nutrition and pharmaceuticals; Smart Materials, offering inorganic materials and polymers; and Technology & Infrastructure, delivering internal site management and logistics services.

The specialty chemicals sector is characterized by innovation and customized solutions rather than bulk commodity production. To gain deeper insights into Evoniks market position, consider exploring its financial performance and competitive landscape on ValueRay.

Headlines to Watch Out For
  • Global industrial production impacts specialty chemicals demand
  • Raw material price volatility affects profit margins
  • Regulatory changes influence chemical product development
  • Automotive sector demand drives additive sales
  • Animal nutrition market trends impact methionine sales
Piotroski VR‑10 (Strict) 4.0
Net Income: 265.0m TTM > 0 and > 6% of Revenue
FCF/TA: 0.03 > 0.02 and ΔFCF/TA -0.78 > 1.0
NWC/Revenue: 11.34% < 20% (prev 9.56%; Δ 1.78% < -1%)
CFO/TA 0.07 > 3% & CFO 1.40b > Net Income 265.0m
Net Debt (3.38b) to EBITDA (1.84b): 1.83 < 3
Current Ratio: 1.48 > 1.5 & < 3
Outstanding Shares: last quarter (466.0m) vs 12m ago 0.0% < -2%
Gross Margin: 23.06% > 18% (prev 0.25%; Δ 2.28k% > 0.5%)
Asset Turnover: 72.22% > 50% (prev 76.74%; Δ -4.52% > 0%)
Interest Coverage Ratio: 2.94 > 6 (EBITDA TTM 1.84b / Interest Expense TTM 217.0m)
Altman Z'' 2.64
A: 0.08 (Total Current Assets 4.92b - Total Current Liabilities 3.33b) / Total Assets 19.21b
B: 0.37 (Retained Earnings 7.17b / Total Assets 19.21b)
C: 0.03 (EBIT TTM 639.0m / Avg Total Assets 19.48b)
D: 0.63 (Book Value of Equity 6.94b / Total Liabilities 11.04b)
Altman-Z'' Score: 2.64 = A
Beneish M -2.98
DSRI: 1.03 (Receivables 1.64b/1.71b, Revenue 14.07b/15.16b)
GMI: 1.07 (GM 23.06% / 24.66%)
AQI: 1.11 (AQ_t 0.38 / AQ_t-1 0.35)
SGI: 0.93 (Revenue 14.07b / 15.16b)
TATA: -0.06 (NI 265.0m - CFO 1.40b) / TA 19.21b)
Beneish M-Score: -2.98 (Cap -4..+1) = A
What is the price of EVK shares? As of April 04, 2026, the stock is trading at EUR 16.75 with a total of 1,910,382 shares traded.
Over the past week, the price has changed by +0.85%, over one month by +22.74%, over three months by +23.47% and over the past year by -8.93%.
Is EVK a buy, sell or hold? Evonik Industries has no consensus analysts rating.
What are the forecasts/targets for the EVK price?
Wallstreet Target Price 15.7 -6%
Analysts Target Price - -
EVK Fundamental Data Overview as of 03 April 2026
Market Cap USD = 8.84b (7.62b EUR * 1.159 EUR.USD)
P/E Trailing = 28.7018
P/E Forward = 19.9203
P/S = 0.5419
P/B = 0.9625
P/EG = 6.2284
Revenue TTM = 14.07b EUR
EBIT TTM = 639.0m EUR
EBITDA TTM = 1.84b EUR
Long Term Debt = 2.59b EUR (from longTermDebt, last quarter)
Short Term Debt = 576.0m EUR (from shortTermDebt, last quarter)
Debt = 3.87b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.38b EUR (from netDebt column, last quarter)
Enterprise Value = 10.88b EUR (7.62b + Debt 3.87b - CCE 619.0m)
Interest Coverage Ratio = 2.94 (Ebit TTM 639.0m / Interest Expense TTM 217.0m)
EV/FCF = 16.78x (Enterprise Value 10.88b / FCF TTM 648.0m)
FCF Yield = 5.96% (FCF TTM 648.0m / Enterprise Value 10.88b)
FCF Margin = 4.61% (FCF TTM 648.0m / Revenue TTM 14.07b)
Net Margin = 1.88% (Net Income TTM 265.0m / Revenue TTM 14.07b)
Gross Margin = 23.06% ((Revenue TTM 14.07b - Cost of Revenue TTM 10.83b) / Revenue TTM)
Gross Margin QoQ = 20.25% (prev 18.17%)
Tobins Q-Ratio = 0.57 (Enterprise Value 10.88b / Total Assets 19.21b)
Interest Expense / Debt = 1.39% (Interest Expense 54.0m / Debt 3.87b)
Taxrate = 47.37% (18.0m / 38.0m)
NOPAT = 336.3m (EBIT 639.0m * (1 - 47.37%))
Current Ratio = 1.48 (Total Current Assets 4.92b / Total Current Liabilities 3.33b)
Debt / Equity = 0.48 (Debt 3.87b / totalStockholderEquity, last quarter 8.11b)
Debt / EBITDA = 1.83 (Net Debt 3.38b / EBITDA 1.84b)
Debt / FCF = 5.21 (Net Debt 3.38b / FCF TTM 648.0m)
Total Stockholder Equity = 8.53b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.36% (Net Income 265.0m / Total Assets 19.21b)
RoE = 3.11% (Net Income TTM 265.0m / Total Stockholder Equity 8.53b)
RoCE = 5.74% (EBIT 639.0m / Capital Employed (Equity 8.53b + L.T.Debt 2.59b))
RoIC = 3.50% (NOPAT 336.3m / Invested Capital 9.60b)
WACC = 4.25% (E(7.62b)/V(11.49b) * Re(6.04%) + D(3.87b)/V(11.49b) * Rd(1.39%) * (1-Tc(0.47)))
Discount Rate = 6.04% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
[DCF] Terminal Value 86.57% ; FCFF base≈716.8m ; Y1≈733.6m ; Y5≈815.2m
[DCF] Fair Price = 44.60 (EV 24.16b - Net Debt 3.38b = Equity 20.78b / Shares 466.0m; r=6.0% [WACC]; 5y FCF grow 2.21% → 3.0% )
EPS Correlation: -34.71 | EPS CAGR: -35.13% | SUE: 0.65 | # QB: 0
Revenue Correlation: -88.56 | Revenue CAGR: -7.17% | SUE: 0.73 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.38 | Chg7d=+0.055 | Chg30d=+0.050 | Revisions Net=+0 | Analysts=2
EPS current Year (2026-12-31): EPS=1.17 | Chg7d=+0.028 | Chg30d=+0.005 | Revisions Net=+0 | Growth EPS=-14.2% | Growth Revenue=-0.0%
EPS next Year (2027-12-31): EPS=1.37 | Chg7d=+0.021 | Chg30d=+0.007 | Revisions Net=+1 | Growth EPS=+17.8% | Growth Revenue=+2.3%
[Analyst] Revisions Ratio: +0.00 (2 Up / 2 Down within 30d for Current Year)
[Growth] Implied Growth Rate = 4.4% (Discount Rate 7.9% - Earnings Yield 3.5%)
[Growth] Growth Spread = -3.2% (Analyst 1.2% - Implied 4.4%)